within Pharmacolibrary.Drugs.ATC.C;

model C08CA14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 0.0005549999999999999,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0124,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010883333333333333,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08CA14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cilnidipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension. It blocks both L-type and N-type calcium channels and is widely used in several Asian countries, including Japan and India. Cilnidipine is approved and used for hypertension management today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult male volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Diwan, R, et al., &amp; Aggarwal, V (2021). Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. <i>Pharmaceutical development and technology</i> 26(3) 278–290. DOI:<a href=&quot;https://doi.org/10.1080/10837450.2020.1864643&quot;>10.1080/10837450.2020.1864643</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33319618/&quot;>https://pubmed.ncbi.nlm.nih.gov/33319618</a></p></li><li><p>Karemore, MN, &amp; Bali, NR (2021). Gellan gum based gastroretentive tablets for bioavailability enhancement of cilnidipine in human volunteers. <i>International journal of biological macromolecules</i> 174 424–439. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2021.01.199&quot;>10.1016/j.ijbiomac.2021.01.199</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33539955/&quot;>https://pubmed.ncbi.nlm.nih.gov/33539955</a></p></li><li><p>Diwan, R, et al., &amp; Aggarwal, V (2020). Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. <i>Colloids and surfaces. B, Biointerfaces</i> 193 111073–None. DOI:<a href=&quot;https://doi.org/10.1016/j.colsurfb.2020.111073&quot;>10.1016/j.colsurfb.2020.111073</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32388122/&quot;>https://pubmed.ncbi.nlm.nih.gov/32388122</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08CA14;
